Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
Social Studies of Science
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Rasmussen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Moral Economy of the Drug Company–Medical Scientist Collaboration in Interwar America

Nicolas Rasmussen

School of History and Philosophy of Science, LG 18 Morven Brown Bldg, University of New South Wales, Sydney 2052, Australia; fax: +61 2 9385 8003Nicolas.Rasmussen{at}unsw.edu.au

This paper explores the exchange relationships underlying collaborations between pharmaceutical companies and preclinical (laboratory-based) researchers, in universities and similar contexts, during the interwar period. It also examines the arguments advanced to justify such collaborations in particular contexts as a way of investigating the perceived costs and benefits, especially among the academic parties in these collaborations, and the way these collaborations were regarded in the US biomedical research community.

Key Words: biochemistry • endocrinology • intellectual property • pharmaceuticals • vitamins

Social Studies of Science, Vol. 34, No. 2, 161-185 (2004)
DOI: 10.1177/0306312704042623
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Social Studies of ScienceHome page
M. P. Jones
Entrepreneurial Science: The Rules of the Game
Social Studies of Science, December 1, 2009; 39(6): 821 - 851.
[Abstract] [PDF]

Home page
 ENTERPRISE SOCHome page
D. A. Tobbell
Pharmaceutical Networks: The Political Economy of Drug Development in the United States, 1945-1980
Enterprise Soc., December 1, 2009; 10(4): 675 - 686.
[Full Text] [PDF]

Home page
 Social Studies of ScienceHome page
J. Abraham and C. Davis
Drug evaluation and the permissive principle: continuities and contradictions between standards and practices in antidepressant regulation.
Social Studies of Science, August 1, 2009; 39(4): 569 - 598.
[Abstract] [PDF]

Home page
 SociologyHome page
J. Abraham
Building on Sociological Understandings of the Pharmaceutical Industry or Reinventing the Wheel? Response to Joan Busfield's `Pills, Power, People'
Sociology, August 1, 2007; 41(4): 727 - 736.
[PDF]

Home page
 Social Studies of ScienceHome page
P. Mirowski and R. Van Horn
The Contract Research Organization and the Commercialization of Scientific Research
Social Studies of Science, August 1, 2005; 35(4): 503 - 548.
[Abstract] [PDF]

Home page
 Social Studies of ScienceHome page
S. Sismondo
Pharmaceutical Maneuvers
Social Studies of Science, April 1, 2004; 34(2): 149 - 159.
[PDF]